Skip to main content
. 2013 Feb 14;144(1):200–207. doi: 10.1378/chest.12-2431

Figure 1.

Figure 1.

Study design, with randomization schemes for part 1 and part 2. A, Part 1 included two panels of subjects (three subjects per group) with repeat dosing and crossover design. B, Part 2 doses were determined using a Bayesian dose-response analysis and administered in the crossover design. A:P = active:placebo dosing ratio; MTD = maximally tolerated dose up to 1.6 mg.